Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular ...

When does Outlook Therapeutics plan to resubmit the BLA for ONS-5010? Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.